Ken Maynard, Melissa LoPresti, Ionela Iacobas, Peter Kan, Sandi Lam
{"title":"抗血管生成剂作为小儿颅内动静脉畸形的新型治疗方法:病例报告。","authors":"Ken Maynard, Melissa LoPresti, Ionela Iacobas, Peter Kan, Sandi Lam","doi":"10.3171/2019.7.PEDS1976","DOIUrl":null,"url":null,"abstract":"<p><p>Intracerebral arteriovenous malformations (AVMs) are high-flow collections of abnormal vessels and a common cause of pediatric intracranial hemorrhage. There are few treatment options available for AVMs not amenable to surgical resection, endovascular embolization, radiosurgery, or multimodality treatment. The authors sought to review the molecular and genetic pathways that have been implicated in the formation of AVMs, focusing on the possibility of medically targeting these pathways in the treatment of AVMs. In the novel case presented here, a pediatric patient who was diagnosed with an intracranial AVM unamenable to conventional treatments underwent alternative treatment with molecular pathway inhibitors.</p>","PeriodicalId":9213,"journal":{"name":"Botanical Gazette","volume":"83 1","pages":"673-679"},"PeriodicalIF":0.0000,"publicationDate":"2019-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Antiangiogenic agent as a novel treatment for pediatric intracranial arteriovenous malformations: case report.\",\"authors\":\"Ken Maynard, Melissa LoPresti, Ionela Iacobas, Peter Kan, Sandi Lam\",\"doi\":\"10.3171/2019.7.PEDS1976\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Intracerebral arteriovenous malformations (AVMs) are high-flow collections of abnormal vessels and a common cause of pediatric intracranial hemorrhage. There are few treatment options available for AVMs not amenable to surgical resection, endovascular embolization, radiosurgery, or multimodality treatment. The authors sought to review the molecular and genetic pathways that have been implicated in the formation of AVMs, focusing on the possibility of medically targeting these pathways in the treatment of AVMs. In the novel case presented here, a pediatric patient who was diagnosed with an intracranial AVM unamenable to conventional treatments underwent alternative treatment with molecular pathway inhibitors.</p>\",\"PeriodicalId\":9213,\"journal\":{\"name\":\"Botanical Gazette\",\"volume\":\"83 1\",\"pages\":\"673-679\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-10-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Botanical Gazette\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3171/2019.7.PEDS1976\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2019/12/1 0:00:00\",\"PubModel\":\"Print\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Botanical Gazette","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3171/2019.7.PEDS1976","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/12/1 0:00:00","PubModel":"Print","JCR":"","JCRName":"","Score":null,"Total":0}
Antiangiogenic agent as a novel treatment for pediatric intracranial arteriovenous malformations: case report.
Intracerebral arteriovenous malformations (AVMs) are high-flow collections of abnormal vessels and a common cause of pediatric intracranial hemorrhage. There are few treatment options available for AVMs not amenable to surgical resection, endovascular embolization, radiosurgery, or multimodality treatment. The authors sought to review the molecular and genetic pathways that have been implicated in the formation of AVMs, focusing on the possibility of medically targeting these pathways in the treatment of AVMs. In the novel case presented here, a pediatric patient who was diagnosed with an intracranial AVM unamenable to conventional treatments underwent alternative treatment with molecular pathway inhibitors.